



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61K 31/444* (2006.01)
A61K 31/506 (2006.01) *A61P 31/16* (2006.01)

(21) International Application Number:

PCT/US2012/049097

(22) International Filing Date:

1 August 2012 (01.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/513,793 1 August 2011 (01.08.2011) US

(71) Applicant (for all designated States except US): VERTEX
PHARMACEUTICALS INCORPORATED [US/US];
130 Waverly Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHARIFSON, Paul, S. [US/US]; 7 Dartmouth Drive, Framingham, MA 01701 (US). CLARK, Michael, P. [US/US]; 30 Kenney Lane, Concord, MA 01742 (US). BANDARAGE, Upul, K. [US/US]; 11 Bates Road, Lexington, MA 02421 (US). BETHIEL, Randy, S. [US/US]; 314 Massachusetts Avenue, Lexington, MA 02420 (US). BOYD, Michael, J. [CA/US]; 69 Florence Street, #2, Winchester, MA 01890 (US). DAVIES, Iona [RO/US]; 38 Fairview Avenue, Waretown, MA 02472 (US). DENG, Hongbo [CN/MA]; 178 Woodland Road, Southborough, MA 01772 (US). DUFFY, John, P. [US/US]; 175 Carriage Hill Road, Northborough, MA 01532 (US). FARMER, Luc, J. [CA/CA]; 5220 Earncliffe, Montreal, QC H3X 2P5 (CA). GAO, Huai [CN/US]; 82 Summer Street, Unit #7, Arlington, MA 02474 (US). GU, Wenxin [CN/MA]; 2 Dunbar Way, Concord, MA 01742 (US). KENNEDY, Joseph, M. [US/US]; 28 Pleasant Street, #1, Charlestown, MA 02129 (US). LEDFORD, Brian [US/US]; 53 Maple Street,

Norton, MA 02766 (US). LEDEBOER, Mark, W. [US/US]; 36 Faulkner Hill Road, Acton, MA 01720 (US). MALTAIS, Francois [US/US]; 24 Randolph Drive, Tewksbury, MA 01876 (US). PEROLA, Emanuele [IT/US]; 6 Lanark Road, Unit #3, Cambridge, MA (US). WANG, Tiansheng [US/US]; 50 Sarah Way, Concord, MA 01742 (US).

(74) Agent: LIM, Booyong, Shim; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF INFLUENZA VIRUSES REPLICATION



(57) Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

